Rznomics FY 2025 Annual ReportBeta
Rznomics annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 23, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
Rznomics FY 2025 Annual Report Analysis
Business Overview
- • Core business: RNA trans-splicing ribozyme platform for gene therapy and circular RNA platform, focused on oncology, rare diseases, degenerative diseases
- • 2025 KOSDAQ listing with IPO on Dec 18, 2025, net proceeds KRW 44.68B for operations and R&D
Management Discussion & Analysis
- • Revenue KRW 7.92B in 2025 from research collaboration and license fees with global pharma, operating loss KRW 14.6B, net loss KRW 103.8B
- • Largest revenue driver: research collaboration and license contracts generating KRW 7.92B, enabled by stable clinical trials of gene therapy RZ-001
Risk Factors
- • USD 1,223,160 and AUD 11,595 accounts payable exposure as of FY2025 end, doubled USD payables from prior period
- • Derivative liabilities zero for FY2025, down from KRW 68.7B derivative liabilities at prior year-end
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding